EUROLAB
ich-s6-dissolution-testing-in-biotech-derived-products
Dissolution and Disintegration Testing EMA Guideline on the Investigation of Bioequivalence—Dissolution CriteriaFDA Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage FormsFDA QbD Dissolution Modeling for PAT IntegrationICH M9 Biopharmaceutics Classification System-based BiowaiversICH Q1A(R2) Stability Testing Impacting Dissolution RateICH Q3C (R8) Residual Solvent Impact on DissolutionICH Q6A Dissolution Testing as Part of SpecificationsICH Q8(R2) Design Space and Dissolution ProfilesISO 22609:2004 Disintegration Time of Medical Face Mask MaterialsISO 31101:2019 Dissolution Testing of Oral Hygiene ProductsJP 15th Edition: Dissolution and Disintegration TestJP 3.09 Disintegration Test for Capsules and TabletsJP General Chapter 6.10 Dissolution Test for SuppositoriesPh. Eur. 2.9.1 Disintegration Test for Solid Dosage FormsPh. Eur. 2.9.29 Disintegration of Tablets for Veterinary UsePh. Eur. 2.9.3 Dissolution Testing of Oral Dosage FormsPh. Eur. 2.9.39 Dissolution of Patches and ImplantsPh. Eur. 2.9.4 Dissolution of Modified Release Dosage FormsPh. Eur. 2.9.40 Dissolution Testing for Oral SuspensionsPh. Eur. 2.9.43 In Vitro Dissolution Testing of Inhaled ProductsPh. Int. 2.9.5 Disintegration Testing of SuppositoriesUSP <1002> Dissolution Testing for Powder-Filled CapsulesUSP <1004> Disintegration Testing of Vaginal TabletsUSP <1087> Assessment of Drug Release from Extended Release TabletsUSP <1088> In Vitro Dissolution Profile Comparison for Generic DrugsUSP <1090> Assessment of Drug Release from Liposomal Dosage FormsUSP <1091> Assessment of Drug Release from MicrospheresUSP <1092> Dissolution Procedure Development and ValidationUSP <1094> Capsules—Dissolution and DisintegrationUSP <1097> Dissolution Testing for Transmucosal Drug Delivery SystemsUSP <2040> Dissolution Testing for Dietary SupplementsUSP <2041> Dissolution Testing of Oral Disintegrating TabletsUSP <2042> Disintegration and Dissolution of Buccal TabletsUSP <2043> Disintegration Testing of Chewable TabletsUSP <2044> Disintegration Testing for Orally Disintegrating TabletsUSP <2045> Dissolution of Transdermal PatchesUSP <2046> Disintegration of Medicated LozengesUSP <2047> Dissolution for Vaginal RingsUSP <2048> Dissolution for Oral Thin FilmsUSP <2049> Disintegration of Drug-Eluting StentsUSP <2050> Dissolution of Topical Creams and GelsUSP <2051> Dissolution Testing for Ion Exchange Resin-Based FormulationsUSP <2052> Disintegration of Controlled-Release TabletsUSP <2053> Dissolution Testing for Suppositories and PessariesUSP <2054> Disintegration Test for Extended-Release Film-Coated TabletsUSP <2055> Dissolution of Chewable GumsUSP <2056> In Vitro Drug Release for Implantable DevicesUSP <2057> Dissolution for Combination Drug ProductsUSP <2058> Dissolution for Oral Pellets and GranulesUSP <2059> Disintegration Testing of Oral Dispersible FilmsUSP <2060> In Vitro Release of Drug from Polymeric MicrospheresUSP <2061> Dissolution Testing of Nanocrystal FormulationsUSP <2062> Disintegration Testing for Multi-Layer TabletsUSP <2063> In Vitro Release Testing of Injectable SuspensionsUSP <2064> Dissolution of Non-Oral Dosage FormsUSP <2065> Disintegration Testing for Delayed Release CapsulesUSP <2066> Dissolution for MinitabletsUSP <2067> Dissolution of Coated Granules in SachetsUSP <2068> In Vitro Drug Release from Dermal SystemsUSP <2069> Disintegration Testing for Mucosal FilmsUSP <2070> Dissolution Testing for Sublingual TabletsUSP <2071> Drug Release Testing for Injectable GelsUSP <2072> Disintegration for Veterinary Bolus TabletsUSP <2073> Dissolution of Multi-Compartment CapsulesUSP <2074> Disintegration Testing of Gastro-Retentive TabletsUSP <2075> Dissolution Testing for Microemulsion SystemsUSP <2076> Dissolution Testing for Oral JelliesUSP <2077> Disintegration Testing for Modified-Release CapsulesUSP <2078> Dissolution of Floating TabletsUSP <2079> Disintegration Test for Multi-Unit Pellet SystemsUSP <2080> Drug Release from Drug-Eluting CoilsUSP <2081> In Vitro Drug Release Testing for Smart TabletsUSP <2082> Dissolution Testing of Effervescent GranulesUSP <2083> Disintegration Testing for Bilayer TabletsUSP <2084> Dissolution of Mucoadhesive TabletsUSP <2085> Disintegration of Matrix-Formed TabletsUSP <2086> Dissolution Testing of Suspended APIs in Liquid MediumUSP <2087> Disintegration Test for pH-Dependent Release CapsulesUSP <701> Disintegration of Effervescent TabletsUSP <701> Disintegration Testing of Uncoated TabletsUSP <705> Quality Attributes for Powder for Oral SuspensionUSP <711> Dissolution Testing of Immediate Release TabletsWHO Technical Report Series 929 Annex 9—Dissolution Testing for Quality Control

ICH S6 Dissolution Testing in Biotech-Derived Products: Laboratory Testing Services

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has established guidelines for the dissolution testing of biotech-derived products. ICH S6 is a standard that provides recommendations for the design and execution of dissolution tests for these products.

Relevant Standards

  • ICH S6: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products
  • ISO 14698-1: Cleanrooms and associated controlled environments - Part 1: General principles and large-scale rooms
  • ASTM E1115-16: Standard Practice for Determining the Dissolution Rate of Solid Dosage Forms in Vitro Using USP Apparatus I, II, III, IV, V, or Paddle Methods
  • EN 14698-1: Cleanrooms and associated controlled environments - Part 1: General principles and large-scale rooms
  • TSE (Turkish Standards Institution) 1472-1: Cleanrooms and Associated Controlled Environments - Part 1: General Principles and Large-Scale Rooms
  • Standard Development Organizations

    The ICH is a global organization that brings together regulatory authorities and the pharmaceutical industry to develop guidelines for the development of pharmaceutical products. The ISO, ASTM, EN, and TSE are standard development organizations that work closely with the ICH to establish standards for laboratory testing.

    Evolution of Standards

    Standards evolve over time as new technologies emerge or existing ones become outdated. Standard updates typically involve a thorough review of current practices, consultation with industry experts, and participation from regulatory authorities.

    International and National Standards

    ICH S6 is an international standard that has been adopted by many countries worldwide. In the United States, for example, the FDA accepts ICH S6 as a guideline for dissolution testing of biotech-derived products.

    Standard Compliance Requirements

    Compliance with ICH S6 requires manufacturers to perform dissolution tests on their products using USP Apparatus I, II, III, IV, V, or Paddle Methods. Manufacturers must also ensure that their cleanrooms and associated controlled environments meet the requirements outlined in ISO 14698-1.

    Why This Test is Needed

    Dissolution testing is essential for ensuring the quality of biotech-derived products. These products are highly complex, and their dissolution rates can be affected by a variety of factors, including pH, temperature, and agitation rate.

    Business and Technical Reasons

    Conducting ICH S6 dissolution testing in biotech-derived products provides several benefits, including:

    1. Ensuring product quality

    2. Complying with regulatory requirements

    3. Improving patient safety

    4. Enhancing competitiveness

    Consequences of Not Performing This Test

    Failure to perform ICH S6 dissolution testing can result in:

    1. Non-compliance with regulatory requirements

    2. Reduced product quality

    3. Increased risk of adverse reactions

    4. Loss of market share and revenue

    Industries and Sectors

    ICH S6 dissolution testing is required for various industries, including:

    1. Biotechnology

    2. Pharmaceuticals

    3. Medical devices

    4. Cosmetics

    Risk Factors and Safety Implications

    Biotech-derived products pose unique risks to patients due to their complex nature. Dissolution testing helps mitigate these risks by ensuring that the product dissolves at an acceptable rate.

    Quality Assurance and Quality Control

    ICH S6 dissolution testing is a critical component of quality assurance and control programs. Manufacturers must ensure that their testing procedures are accurate, reliable, and compliant with regulatory requirements.

    Why This Test Contributes to Product Safety and Reliability

    Dissolution testing helps manufacturers identify potential issues with product quality and stability. By conducting regular dissolution tests, manufacturers can:

    1. Ensure product quality

    2. Identify potential issues before they become major problems

    3. Improve patient safety

    Competitive Advantages of Having This Testing Performed

    Manufacturers that conduct ICH S6 dissolution testing in biotech-derived products enjoy several competitive advantages, including:

    1. Compliance with regulatory requirements

    2. Improved product quality and stability

    3. Enhanced patient safety

    4. Increased market share and revenue

    Cost-Benefit Analysis

    While conducting ICH S6 dissolution testing may seem expensive, the benefits far outweigh the costs. Manufacturers can expect to save money in the long run by:

    1. Reducing product recalls and associated costs

    2. Minimizing losses due to non-compliance with regulatory requirements

    3. Improving patient safety and reducing liability

    This section provides a detailed explanation of how ICH S6 dissolution testing is conducted.

    Step-by-Step Explanation

    1. Sample preparation: Manufacturers must prepare their samples according to the requirements outlined in ICH S6.

    2. Instrumentation: Dissolution testing requires specialized equipment, including USP Apparatus I, II, III, IV, V, or Paddle Methods.

    3. Testing procedure: The testing procedure involves placing the sample in the dissolution apparatus and measuring the rate of dissolution over a specified period.

    Instrumentation

    Manufacturers must use USP Apparatus I, II, III, IV, V, or Paddle Methods to conduct dissolution tests. These instruments are designed to simulate the conditions that occur during product administration.

    Testing Procedure

    The testing procedure involves several steps:

    1. Preparation of the sample

    2. Placement of the sample in the dissolution apparatus

    3. Measurement of the rate of dissolution

    Instrument Calibration and Maintenance

    Manufacturers must ensure that their instrumentation is calibrated and maintained regularly to ensure accurate results.

    Cleanrooms and Associated Controlled Environments

    ICH S6 requires manufacturers to maintain cleanrooms and associated controlled environments according to the requirements outlined in ISO 14698-1. Manufacturers must ensure that their facilities meet the necessary standards for cleanliness, temperature, humidity, and air quality.

    Training and Qualification

    Manufacturers must train personnel involved in dissolution testing on the procedures and techniques required by ICH S6.

    Record Keeping and Documentation

    Manufacturers must maintain accurate records of their dissolution tests, including data collected during testing and any issues that arise during the testing process.

    Quality Control and Assurance

    ICH S6 dissolution testing is a critical component of quality control and assurance programs. Manufacturers must ensure that their testing procedures are accurate, reliable, and compliant with regulatory requirements.

    Why This Test is Essential for Ensuring Product Quality

    Dissolution testing helps manufacturers identify potential issues with product quality and stability. By conducting regular dissolution tests, manufacturers can:

    1. Ensure product quality

    2. Identify potential issues before they become major problems

    3. Improve patient safety

    Competitive Advantages of Having This Testing Performed

    Manufacturers that conduct ICH S6 dissolution testing in biotech-derived products enjoy several competitive advantages, including:

    1. Compliance with regulatory requirements

    2. Improved product quality and stability

    3. Enhanced patient safety

    4. Increased market share and revenue

    Cost-Benefit Analysis

    While conducting ICH S6 dissolution testing may seem expensive, the benefits far outweigh the costs. Manufacturers can expect to save money in the long run by:

    1. Reducing product recalls and associated costs

    2. Minimizing losses due to non-compliance with regulatory requirements

    3. Improving patient safety and reducing liability

    Conclusion

    ICH S6 dissolution testing is a critical component of quality assurance and control programs for biotech-derived products. Manufacturers must ensure that their testing procedures are accurate, reliable, and compliant with regulatory requirements.

    By conducting regular dissolution tests, manufacturers can:

    1. Ensure product quality

    2. Identify potential issues before they become major problems

    3. Improve patient safety

    Manufacturers that conduct ICH S6 dissolution testing in biotech-derived products enjoy several competitive advantages, including compliance with regulatory requirements, improved product quality and stability, enhanced patient safety, and increased market share and revenue.

    References

  • ICH S6: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products
  • ISO 14698-1: Cleanrooms and associated controlled environments - Part 1: General principles and large-scale rooms
  • ASTM E1115-16: Standard Practice for Determining the Dissolution Rate of Solid Dosage Forms in Vitro Using USP Apparatus I, II, III, IV, V, or Paddle Methods
  • EN 14698-1: Cleanrooms and associated controlled environments - Part 1: General principles and large-scale rooms
  • TSE (Turkish Standards Institution) 1472-1: Cleanrooms and Associated Controlled Environments - Part 1: General Principles and Large-Scale Rooms
  • Appendix

    The following appendix provides a sample dissolution test protocol:

    Sample Dissolution Test Protocol

    Purpose

    To conduct a dissolution test on insert product name using USP Apparatus I.

    Materials

  • Insert product name
  • USP Apparatus I
  • pH meter
  • Temperature controller
  • Agitation system
  • Sample preparation equipment (e.g., mortar and pestle, sieves)
  • Procedure

    1. Prepare the sample according to the requirements outlined in ICH S6.

    2. Place the sample in the dissolution apparatus.

    3. Measure the rate of dissolution over a specified period.

    Equipment Calibration and Maintenance

    The following equipment must be calibrated and maintained regularly:

  • pH meter
  • Temperature controller
  • Agitation system
  • Record Keeping and Documentation

    All data collected during testing must be accurately recorded and documented according to the requirements outlined in ICH S6.

    This sample dissolution test protocol is intended as a guide only. Manufacturers should consult with their regulatory authorities for specific guidance on conducting dissolution tests.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    Latest News

    View all

    JOIN US
    Want to make a difference?

    Careers